Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference

Rhea-AI Summary

Protagonist Therapeutics (NASDAQ:PTGX) announced that its President and CEO, Dinesh V. Patel, will join a fireside chat at the Jefferies Virtual 2020 London Healthcare Conference. The event is scheduled for November 17, 2020, at 5:35 p.m. GMT (12:35 p.m. EST). A live and archived webcast will be accessible via the company's website and the provided links.

Protagonist is a clinical-stage biopharmaceutical company focusing on developing peptide-based therapeutics for significant medical needs, currently advancing three clinical-stage assets.

NEWARK, Calif., Nov. 11, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference.

Presentation details:
Date: Tuesday, Nov. 17, 2020
Time: 5:35 p.m. GMT (12:35 p.m. EST)

A live and archived webcast of the event will be available at https://wsw.com/webcast/jeff141/ptgx/1873875 and in the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. In addition to PTG-200, two oral peptide interleukin-23 receptor antagonist candidates from a collaboration with Janssen Biotech, Inc., are in development and have been selected for advancement into clinical studies. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference-301171288.html

SOURCE Protagonist Therapeutics, Inc.

FAQ

When is Protagonist Therapeutics' fireside chat at the Jefferies Virtual 2020 London Healthcare Conference?

The fireside chat is scheduled for November 17, 2020, at 5:35 p.m. GMT (12:35 p.m. EST).

Who will represent Protagonist Therapeutics at the Jefferies Virtual Conference?

Dinesh V. Patel, Ph.D., President and CEO, will represent Protagonist Therapeutics.

Where can I watch the Protagonist Therapeutics conference webcast?

The webcast will be available live and archived on Protagonist's website and through the provided links.

What is the focus of Protagonist Therapeutics as a biopharmaceutical company?

Protagonist Therapeutics focuses on developing novel peptide-based therapeutics for significant unmet medical needs.

What clinical assets are currently being developed by Protagonist Therapeutics?

Protagonist has three clinical-stage assets, including PTG-300 and PTG-200, targeting blood disorders and inflammatory bowel disease.